STOCK TITAN

[SCHEDULE 13G/A] ANGIODYNAMICS INC Amended Passive Investment Disclosure

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

AngioDynamics, Inc. received an amended Schedule 13G/A from Divisadero Street Capital Management and related entities, along with William Zolezzi, reporting a very small passive position in its common stock. The group reports beneficial ownership of 4,576 shares, representing 0.01% of AngioDynamics’ outstanding common stock.

The filing shows no sole voting or dispositive power over the shares; all reported power is shared among the reporting persons. All of the securities are directly owned by advisory clients of Divisadero Street Capital Management, and each reporting person disclaims beneficial ownership beyond any pecuniary interest.

The group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of AngioDynamics, and that overall ownership remains at or below 5% of the class.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Divisadero Street Capital Management, LP
Signature:By: Divisadero Street Capital LLC, its general partner, By: /s/ William Zolezzi
Name/Title:William Zolezzi, Manager
Date:02/13/2026
William Zolezzi
Signature:By: /s/ William Zolezzi
Name/Title:William Zolezzi
Date:02/13/2026
Divisadero Street Partners, L.P.
Signature:By: Divisadero Street Partners GP, LLC, its general partner, By: /s/ William Zolezzi
Name/Title:William Zolezzi, Manager
Date:02/13/2026
Divisadero Street Partners GP, LLC
Signature:By: /s/ William Zolezzi
Name/Title:William Zolezzi, Manager
Date:02/13/2026
Divisadero Street Capital, LLC
Signature:By: /s/ William Zolezzi
Name/Title:William Zolezzi, Manager
Date:02/13/2026

Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
Exhibit Information

Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification

FAQ

What does AngioDynamics (ANGO)’s latest Schedule 13G/A disclose?

The Schedule 13G/A discloses that Divisadero Street Capital Management, related entities, and William Zolezzi beneficially own 4,576 shares of AngioDynamics common stock. This represents a very small 0.01% stake and is reported as a passive, non‑control investment position.

How many AngioDynamics (ANGO) shares does Divisadero report owning and what percent is that?

Divisadero Street Capital Management and related reporting persons report beneficial ownership of 4,576 AngioDynamics common shares. This stake equals approximately 0.01% of the company’s outstanding common stock, indicating their position is well below typical significant ownership thresholds such as 5%.

Who are the reporting persons in the AngioDynamics (ANGO) Schedule 13G/A filing?

The reporting persons are Divisadero Street Capital Management, LP, William Zolezzi, Divisadero Street Partners, L.P., Divisadero Street Partners GP, LLC, and Divisadero Street Capital, LLC. They collectively report a small shared beneficial ownership interest in AngioDynamics common stock, primarily through advisory client accounts.

Is the Divisadero position in AngioDynamics (ANGO) an activist or control stake?

The filing characterizes the position as passive. The reporting persons certify the securities were not acquired and are not held to change or influence control of AngioDynamics, and ownership is limited to about 0.01% of the common stock, far below traditional activist levels.

Who directly owns the AngioDynamics (ANGO) shares reported in this Schedule 13G/A?

All securities reported are directly owned by advisory clients of Divisadero Street Capital Management, LP. The reporting persons, including related entities and William Zolezzi, report beneficial ownership and shared voting and dispositive power, while disclaiming ownership beyond any pecuniary interest they may have.

Does Divisadero’s AngioDynamics (ANGO) stake exceed 5% of the company?

No. The filing explicitly states ownership of 5 percent or less of the class. With 4,576 shares representing about 0.01% of AngioDynamics’ common stock, the reported position is far below the 5% level associated with larger, potentially more influential shareholders.
Angiodynamics

NASDAQ:ANGO

ANGO Rankings

ANGO Latest News

ANGO Latest SEC Filings

ANGO Stock Data

454.63M
38.57M
6.84%
93.83%
7.39%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
LATHAM